Clinical trial

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

NCT00132002

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2005-06-01

PhasePHASE2

Study timeline

Study start (unknown)2005-06-01Date precision: month

Registry last updated2015-03-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Male Breast Cancerunresolved

Recurrent Breast Cancerunresolved

Stage IV Breast Cancerunresolved

Interventions

vorinostatDRUG · verified · RxNorm: vorinostat

laboratory biomarker analysisOTHER

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

DuarteCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00132002 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.